Drugs / ASCs
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04615455 | Nov 2020 → Dec 2022 | dry eye syndrome | Rigshospitalet, Denmark | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASCs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04615455 ↗ |
| Modality | Cell therapy | “injection of allogeneic adipose-derived mesenchymal stem cells (ASCs)” NCT04615455 ↗ |
| Route | Other | “One transconjunctival injection of allogeneic ASCs into the LG in one eye.” NCT04615455 ↗ |